Sygnature Discovery

MARCH 14, 2025

High Throughput Screening Workflow The HTS Workflow is tailored to each of our clients requirements, focusing on developing robust assays with a flexible approach, especially in selecting hits to balance false positives and negatives. The process begins with assay development or transfer.

Biochemical Assays 52

Biochemical Assays Fragment Screening Computational Chemistry Assay Development 52

Sygnature Discovery

FEBRUARY 11, 2022

This exciting partnership combines our novel assay development and hit identification expertise with River BioMedics unique, state-of-the-art technology: advanced human-predictive in vitro 3D heart models, plus their deep knowledge of cardiac biology. River BioMedics is progressing its cardiovascular disease programmes following a €1.8m

Assay Development 52

Assay Development Disease Engineering Science 52

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The Pharma Data

JANUARY 27, 2021

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. VANCOUVER, Jan.

FDA 52

FDA Synthetic Chemistry Assay Development Treatment 52

Drug Target Review

OCTOBER 10, 2024

Diseased cells can respond differently to treatment, leading to unforeseen adverse events, including severe toxicity and even death. Addressing unexpected manufacturing challenges, safety concerns, or efficacy issues in later stages can significantly delay clinical development and escalate costs.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

Agency IQ

JULY 21, 2023

As for the second challenge, potential confounders present at the time of treatment initiation can be controlled for using randomization, but it may be more difficult for sponsors to detect and adjust for factors that arise after the investigational product’s administration (e.g.,

FDA 40

FDA Clinical Trials Treatment Trials 40

Agency IQ

FEBRUARY 2, 2024

Predictive biomarkers enable the identification and selection of patients who are more likely to benefit from a specific treatment and would achieve a better clinical outcome in response to a specific treatment. Prognostic biomarkers enable patient selection that would have a better clinical outcome irrespective of treatment.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40